This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walzer, P. D. Articles by White, M. Search for Related Content PubMed PubMed Citation Articles by Walzer, P. D. Articles by White, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Feb 1997, 242-250, Vol 41, No. 2
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies

PD Walzer, J Runck, S Orr, J Foy, P Steele and M White
Research Service, Veterans Affairs Medical Center, Cincinnati, Ohio 45220, USA.

We analyzed single drugs and combinations of drugs used clinically in the treatment of opportunistic infections and other conditions for their activities against Pneumocystis carinii pneumonia in immunosuppressed rats. When they were used alone, atovaquone, rifabutin, and dapsone were more active than clarithromycin or trimethoprim. Drug combinations were evaluated for synergistic activity by an analysis of variance model for two-way factorial experiments and a response surface model. Atovaquone combined with trimethoprim trimethoprim and some combinations of dapsone and clarithromycin was synergistic; however, the activities of combinations of atovaquone and rifabutin, atovaquone and clarithromycin, and atovaquone and dapsone were simply additive. Lovastatin, which inhibits 3-hydroxy- methylglutaryl coenzyme A reductase, was inactive whether it was used alone or in combination with other agents. None of the synergistic drug combinations was as effective as trimethoprim-sulfamethoxazole. We conclude that the rat model can be used to test combinations of anti-P. carinii agents for synergistic activity by well-established statistical techniques. While some combinations of clinically used antimicrobial drugs have enhanced anti-P. carinii activity, further studies are needed before clinical trials can be contemplated.

This article has been cited by other articles:

• Walzer, P. D., Ashbaugh, A. (2002). Use of Terbinafine in Mouse and Rat Models of Pneumocystis carinii Pneumonia. Antimicrob. Agents Chemother. 46: 514-516 [Abstract] [Full Text]  
• Walzer, P. D., Ashbaugh, A., Collins, M., Cushion, M. T. (2001). In Vitro and In Vivo Effects of Quinupristin-Dalfopristin against Pneumocystis carinii. Antimicrob. Agents Chemother. 45: 3234-3237 [Abstract] [Full Text]  
• Ball, M. D., Bartlett, M. S., Shaw, M., Smith, J. W., Nasr, M., Meshnick, S. R. (2001). Activities and Conformational Fitting of 1,4-Naphthoquinone Derivatives and Other Cyclic 1,4-Diones Tested In Vitro against Pneumocystis carinii. Antimicrob. Agents Chemother. 45: 1473-1479 [Abstract] [Full Text]  
• Cirioni, O., Giacometti, A., Barchiesi, F., Scalise, G. (2000). Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 46: 577-582 [Abstract] [Full Text]  
• Cirioni, O., Giacometti, A., Barchiesi, F., Fortuna, M., Scalise, G. (1999). In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. J Antimicrob Chemother 44: 653-659 [Abstract] [Full Text]